

EXPLANATORY NOTE

The sole purpose of this Form 8-K/A is to amend the Form 8-K, filed by Pieris Pharmaceuticals, Inc. with the Securities and Exchange Commission on November 18, 2021, to add Inline eXtensible Business Reporting Language ("XBRL") tagging to the cover page and to furnish Exhibit 104 relating to the same. No other changes have been made.

Item 7.01 Regulation FD Disclosure.

Attached hereto as Exhibit 99.1 and incorporated by reference herein is the November 2021 Investor Presentation of Pieris Pharmaceuticals, Inc.

The information set forth under this “Item 7.01. Regulation FD Disclosure,” including Exhibit 99.1 attached hereto, shall not be deemed “filed” for any purpose, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) *Exhibits.*

99.1 [Investor Presentation, Dated November 2021](#).*

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Previously filed

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PIERIS PHARMACEUTICALS, INC.

Dated: January 14, 2022

/s/ Tom Bures

Tom Bures

Chief Financial Officer